AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

SPIKE FLOW Endocardial Lead Safety and Performance Study

RecruitingNAAges 18 Years - anyAllFIAB SpA
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The objective of this study is to assess the safety and performance of the SPIKE FLOW endocardial lead. Primary objectives are to assess: * safety in terms of freedom from Serious Adverse Events(SADEs); * performance in terms of Mean Pacing Capture Threshold. Secondary objectives are to assess: * safety in terms of freedom from Adverse Events (ADEs); * performance in terms of Mean Pacing Impedance; * performance in terms of Sensed R-wave Amplitude. The study is a prospective, non-randomized, single-arm, multi-center investigation in 131 adult subjects with 3 investigational sites in Italy. The study is expected to take approximately 1 year to enroll. Enrolled subjects will have visit timepoints at: baseline, lead insertion, lead removal, discharge and 30 days post lead removal.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Subject undergoing a surgical or an interventional procedure, requiring temporary cardiac pacing per investigator's medical judgment or subjects with bradycardia who are under evaluation to determine if the cause is transient or permanent; * Subject is at least 18 years of age; * Subject provides written informed consent to the study. Exclusion Criteria: * Subject has a co-existing temporary pacing or an implanted active permanent pacemaker or a cardiac defibrillator; * Subject in cardiogenic shock; * Subject is currently in atrial fibrillation; * Subject is pregnant or breastfeeding; * Subject had a stroke within 6 months prior to enrollment; * Subject has renal insufficiency with creatinine \>2 mg/dl; * Subject with known bleeding diathesis; * Subject with a history of deep vein thrombosis or pulmonary embolism within 6 months; * Subject with known tricuspid valve disease that may impede catheter advancement to and withdrawal from the right ventricle; * Subject with known intracardiac thrombus or vegetation on echocardiography; * Subject with significant neck abnormalities such that placement of a right and/or left internal jugular vein line would be difficult; * Subject has an active systemic infection or local infection at or around the insertion site; * Subject is involved in another clinical study that could influence the safety or outcome measures of this study.
๐Ÿ’Š

What it tests

  • Lead insertion
  • lead removal
๐Ÿ“

Where

3 sites
Ospedale Generale Regionale "F. Miulli"
Acquaviva delle Fonti, Italy
Ospedale del Cuore 'G. Pasquinucci' Fondazione Toscana 'Gabriele Monasterio'
Massa, Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, Italy
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy